Kestra Private Wealth Services’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$494K Sell
2,864
-145
-5% -$26.9K 0.01% 1213
2025
Q4
$600K Buy
3,009
+145
+5% +$26.3K 0.01% 1065
2025
Q3
$448K Sell
2,864
-8
-0.3% -$1.27K 0.01% 1157
2025
Q2
$436K Buy
2,872
+943
+49% +$126K 0.01% 1101
2025
Q1
$290K Sell
1,929
-115
-6% -$19.3K ﹤0.01% 1220
2024
Q4
$377K Buy
2,044
+136
+7% +$26.2K 0.01% 1048
2024
Q3
$376K Buy
1,908
+19
+1% +$3.95K 0.01% 1000
2024
Q2
$390K Sell
1,889
-16
-0.8% -$3.63K 0.01% 933
2024
Q1
$516K Buy
1,905
+10
+0.5% +$2.39K 0.01% 784
2023
Q4
$448K Buy
1,895
+95
+5% +$18.7K 0.01% 773
2023
Q3
$353K Buy
1,800
+236
+15% +$48.5K 0.01% 794
2023
Q2
$329K Sell
1,564
-31
-2% -$6.17K 0.01% 788
2023
Q1
$322K Buy
1,595
+78
+5% +$17.7K 0.01% 760
2022
Q4
$331K Buy
+1,517
New +$331K 0.02% 644
2022
Q3
Sell
-2,179
Closed -$466K 920
2022
Q2
$466K Sell
2,179
-16
-0.7% -$3.91K 0.03% 528
2022
Q1
$623K Sell
2,195
-2,566
-54% -$791K 0.03% 505
2021
Q4
$1.79M Buy
4,761
+52
+1% +$20.2K 0.09% 248
2021
Q3
$1.94M Sell
4,709
-80
-2% -$33.2K 0.11% 205
2021
Q2
$1.77M Sell
4,789
-62
-1% -$20.7K 0.11% 214
2021
Q1
$1.41M Sell
4,851
-1,618
-25% -$450K 0.1% 228
2020
Q4
$1.61M Sell
6,469
-100
-2% -$23.8K 0.12% 192
2020
Q3
$1.49M Buy
+6,569
New +$1.36M 0.13% 176

Other funds holding CRL

Kestra Private Wealth Services's CRL Position: Q1 2026 in Review

Kestra Private Wealth Services reduced its Charles River Laboratories (CRL) stake by 4.8% in Q1 2026, selling an estimated $26.9K and leaving 2,864 shares worth $494K. The position accounts for 0.01% of the portfolio, ranked #1213.

Kestra Private Wealth Services first reported a position in CRL in Q3 2020 and has held it in 22 quarters since. The position peaked at $1.94M in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Kestra Private Wealth Services held 2,864 shares of Charles River Laboratories worth $494K as of Q1 2026.
  • Kestra Private Wealth Services sold 145 Charles River Laboratories shares in Q1 2026, an estimated $26.9K.
  • Charles River Laboratories made up 0.01% of Kestra Private Wealth Services's portfolio in Q1 2026, its #1213 holding.
  • Kestra Private Wealth Services first reported a position in Charles River Laboratories in Q3 2020 and has held it in 22 quarters since.
  • Kestra Private Wealth Services's Charles River Laboratories position peaked at $1.94M in Q3 2021.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Kestra Private Wealth Services's 13F filing for Q1 2026, filed 20 Apr 2026.